Abstract
Six cell lines have been generated from the human fibrosarcoma HT-1080 by mutagenesis. They were selected on the basis of reduced urokinase (uPA) binding on replicate polyester filters. Single cell clones were then isolated by limited dilution cloning. All cloned cells showed less uPA binding on filters, and as cell monolayers. These cell lines were able to bind only 10 to 65% as much uPA as the wild-type HT-1080 cells. Surface-bound uPA proteolytic activity and surface activation of plasminogen from these cells were also reduced relative to the wild-type. uPA could activate MAP kinases in the wild-type and two of the cell lines with the least uPA-binding, but the amount of the activated forms of the signalling molecules were reduced. Immunoblotting using two different anti-uPA receptor antibodies showed two cross-reacting protein species of ∼ 53 kDa and ∼ 38 kDa. The proportion of the lower M r band to the higher M r band was found to be reduced in all the cell lines relative to the wild-type. Chemical cross-linking with single-chain urokinase (scuPA) showed only one high-molecular-weight adduct, with M r∼90 kDa, in all the cell lines tested. Similarly, cross-linking with the amino terminal fragment of uPA yielded a single ∼70 kDa adduct. These would indicate that only the ∼53 kDa band was responsible for cross-linking reactions. Equilibrium binding experiments showed that only one set of high-affinity binding sites for the wild-type cells. However, the binding of scuPA to two of these cell lines was best fitted to a two-site model, one of which was similar to the high-affinity binding sites of the wild-type, although the number of sites was reduced, while the other was of much lower affinity but was large in number. These results are discussed in relation to changes in the structure of ligand binding machinery in these cells, which affect other cellular functions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Liotta LA, Goldfarb R, Brundage R et al. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenase components of basement membrane. Cancer Res 1981; 41: 4629–36.
Dano K, Andreasen PA, Grondahl-Hansen J et al. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139–266.
Vassalli J, Baccino D, Belin D. A cellular binding site for the M r 55,000 form of human plasminogen activator, urokinase. J Cell Biol 1985; 100: 86–92.
Bajpai A, Baker JB. Cryptic urokinase binding sits on human foreskin fibroblasts. Biochem Biophys Res Commun 1985; 133: 475–9.
Appella E, Robinson EA, Ullrich SJ et al. The receptor binding sequence of urokinase. J Biol Chem 1987; 262: 4437–40.
Stoppelli MP, Corti A, Solfientini A et al. Differentiation-enhanced binding of the amino terminalfragment of human urokinase-type plasminogen activator to its specific receptor. Proc Natl Acad Sci USA 1985; 82: 4939–43.
Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989; 264: 2185–8.
Hoyer-Hansen G, Behrendt N, Ploug M et al. The intact urokinase receptor is required for efficient vitronectin binding: Receptor cleavage prevents ligand interaction. FEBS Letts 1997; 420: 79–85.
Ploug M, Ronne E, Behrendt N et al. Cellular receptor for urokinase plasminogen activator: carboxyl terminal processing and membrane anchoring by glycosyl phosphatidylinositol. J Biol Chem 1991; 266: 1926–33.
Dumler I, Weis A, Mayboroda OA et al. The Jak/Stat pathway and urokinase receptor signalling in human aortic vascular smooth muscle cells. J Biol Chem 1998; 273: 315–21.
Busso N, Masur SK, Lazega D et al. Induction of cell migration by pro-urokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells. J Cell Biol 1994; 126: 259–70.
Tang H, Kerins DM, Hao Q et al. The urokinase-type plasminoen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem 1998; 273: 18268–72.
Nguyen DHD, Hussaini IS, Gonias SL. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular mobility. J Biol Chem 1998; 273: 8502–7.
Ghiso JAA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999; 147: 89–103.
Huang S, New L, Pan Z et al. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38α mitogen-activated protein kinase activity. J Biol Chem 2000; 275: 12266–72.
Jiang Y, Pannel R, Liu, JN, Gurewich V. Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes. Blood 1996; 87: 2775–81.
Kanse SM, Kost C, Benzakour O et al. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterio Thromb &; Vasc Biol 1997; 17: 2828–54.
Koopman JL, Slopm J, de Bart ACW et al. Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor. J Biol Chem 1998; 273: 33267–72.
Kook YH, Adamski J, Selent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994; 13: 3983–91.
Yu W, Kim J, Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 1997; 137: 767–77.
Min HY, Semnani R, Mizukami IF et al. cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. J Immunol 1992; 148: 3636–42.
Deutsch DE, Mertz E. Plasminogen purification from human plasma by affinity chromatography. Science 1970; 170: 1095–7.
Esko JD, Stewart TE, Taylor WH. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc Natl Acad Sci USA 1985; 82: 3197–201.
de Agostini AL, Lau HKF, Leone C et al. Cell mutants defective in synthesizing a heparan sulfate proteoglycan with regions of defined monosaccharide sequence. Proc Natl Acad Sci USA 1990; 87: 9784–8.
Raetz CRH, Wermuth H, McIntyre TM et al. Somatic cell cloning in polyester stacks. Proc Natl Acad Sci USA 1982; 79: 3223–7.
Stoppelli MP, Tacchetti C, Cubellis MV et al. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 1986; 45: 675–84.
Boyd D, Florent G, Kim P, Brattain MG. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 1988; 48: 3112–6.
Fraker JF, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloramide: 1,3,4,6-tetra-chloro-3-β-1α-6α-dip henylglycouril. Biochem Biophys Res Commun 1978; 80: 847–57.
Kung SKP, Lau HKF. Characterization of immunotrap assays for urokinase plasminogen activator and its inhibitors and measurements of these molecules in human plasma and mouse macrophage in culture. Int J Biochem 1993; 25: 781–8.
Kung SKP, Lau HKF. Modulation of the plasminogen activation system in murine macrophages. Biochim Biophys Acta 1993; 1176: 113–22.
Behrendt N, Ronne E, Ploug M et al. The human receptor for urokinase plasminogen activator NH2 terminal acid sequence and glycosylation variants. J Biol Chem 1990; 265: 6453–60.
Laemmli UK. Cleavage of structural proteins during assembly of head bacteriophage T4. Nature 1970; 227: 680–2.
Kovacic B, Ilic D, Damsky CH, Gardner DG. c-Src activation plays a role in endothelin dependent hypertrophy of the cardiac myocyte. J Biol Chem 1998; 273: 35185–93.
Nielsen LS, Kellerman GF, Behrendt N et al. A 55000-60000 Mr receptor protein for urokinase-type plasminogen activator. J Biol Chem 1988; 263: 2358–63.
Hoyer-Hansen G, Ronne E, Solberg H et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992; 267: 18224–9.
Ploug M, Ellis V, Dano K. Ligand interaction between urokinasetype plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 1994; 33: 8991–7.
Moller LB, Pollanen J, Ronne E et al. N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand. J Biol Chem 1993; 268: 11152–9.
Ploug M, Kjalke M, Ronne E et al. Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. J Biol Chem 1993; 268: 17539–46.
Bohuslav J, Horejsi V, Hansmann C et al. Urokinase plasminogen activator receptor, β2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med 1995; 181: 1381–90.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lau, H.K., Teitel, J.M. & Kim, M. Isolation and characterization of cell lines with reduced urokinase binding. Clin Exp Metastasis 18, 29–36 (2000). https://doi.org/10.1023/A:1026521216811
Issue Date:
DOI: https://doi.org/10.1023/A:1026521216811